All In Biotech

Drug Trial Radar · NCT01765881

Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2

Comparison Between 25 µg Vaginal Misoprostol Versus Slow Release Pessary Prostaglandin-E2 (PGE2) : Could we Use Low Dose Vaginal Misoprostol as a First Line Treatment for Induction of Labor ?

Last checked: Nov 20, 2026Latest source record: Apr 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,700 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,700

Actual

Start

Sep 2012

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For about 10% of pregnancies, it is necessary to induce delivery for medical reasons. Prostaglandins alone can be used to perform cervical ripening in cases of immature cervix. In France, dinoprostone is the own approved medication. It is in the form of gel or sustained release device whose effectiveness and side effects are comparable. The vaginal misoprostol has no marketing authorization in France, but is sometimes used. Some data in the scientific literature have showed that its use with low-dose (25 mcg) vaginally did not lead to more complications, was at least as effective and seems to be cost-effective compared with dinoprostone. Misoprostol with this dose and route of administration is now recommended by the American College of Obstetricians and Gynecologist (ACOG), Grade A (ACOG Practice Bulletin August 2009). This is not the case in France (French HAS 2008 Guidelines on induction of labor). According to HAS, the investigators still lack data on large samples to confirm the benefits of misoprostol 25 mcg vaginally, in terms of efficiency, rate of cesarean section, and lower cost compared to dinoprostone. The primary objective is to demonstrate non-inferiority of vaginal misoprostol 25 mcg vs. dinoprostone in terms of cesarian section occurence with a non-inferiority margin of +5% difference.

Conditions

  • Delivery Uterine

Interventions

  • MisoprostolDrug

    administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules

  • DinoprostoneDrug

    administration of one sustained released pessary of 10 milligrams by intravaginal route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cesarean for all indicationsTime frame: Up to delivery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Bicêtre Hospital

    Le Kremlin-Bicêtre, France

  • Hospital Poissy

    Poissy, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

  • University Hospital Toulouse

    Toulouse, France, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.